393509-23-4

Basic information

• Product Name: 2-(5-BroMo-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid
• Synonyms: 2-(5-BroMo-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid;(5-broMo-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid;5-Bromo-7-fluoro-1,2,3,4-tetrahydrocyclopent[b]indole-3-acetic acid
• CAS NO: 393509-23-4
• Molecular Formula: C₁₃H₁₁BrFNO₂
• Molecular Weight: 312.1343432
• Mol File: 393509-23-4.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 506.8°C at 760 mmHg
• Flash Point: 260.3°C
• Appearance: /
• Density: 1.7g/cm³
• Vapor Pressure: 4.31E-11mmHg at 25°C
• Refractive Index: 1.678
• Storage Temp.: 2-8°C(protect from light)
• PKA: 4.55±0.10(Predicted)
• CAS DataBase Reference: 2-(5-BroMo-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(5-BroMo-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid(393509-23-4)
• EPA Substance Registry System: 2-(5-BroMo-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid(393509-23-4)

Safety Data

• Hazardous Substances Data: 393509-23-4(Hazardous Substances Data)

Usage

Description

2-(5-Bromo-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid is a complex chemical compound characterized by a cyclopenta[b]indol ring system, which is substituted with bromine, fluorine, and acetic acid functional groups. This unique structure may allow it to interact with various biological targets, suggesting potential pharmaceutical applications.

Uses

Used in Pharmaceutical Applications:
2-(5-Bromo-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid is used as a potential pharmaceutical agent due to its distinctive molecular structure that could engage with specific biological targets within the body, offering new avenues for therapeutic intervention.
Used in Organic Synthesis:
In the field of organic synthesis, 2-(5-Bromo-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid serves as a valuable building block. Its unique functional groups and ring system make it a promising candidate for the development of new chemical entities with tailored pharmacological properties.
Used in Medicinal Chemistry:
2-(5-Bromo-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid is utilized in medicinal chemistry for the design and synthesis of novel compounds with specific therapeutic effects. Its structural features may contribute to the creation of drugs with improved efficacy and selectivity.

InChI:InChI=1/C13H11BrFNO2/c14-10-5-7(15)4-9-8-2-1-6(3-11(17)18)12(8)16-13(9)10/h4-6,16H,1-3H2,(H,17,18)

Upstream product

• 61272-76-2 4-fluoro-2-iodoaniline 
• 393509-22-3 (+/-) 2-(7-fluoro-1,2,3-trihydrocyclopenta[2,3-b]indol-3-yl)acetic acid 
• 393509-21-2 ethyl (7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetate 
• 371-40-4 4-fluoroaniline 
• 1003-98-1 2-bromo-4-fluoroaniline 
• 20826-94-2 ethyl (2-oxocyclopentyl)acetate 
• 571170-84-8 [2-(2-bromo-4-fluoro-phenylimino)-cyclopentyl]-acetic acid ethyl ester 

Downstream Products

• 393509-05-2 [(3R)-5-bromo-4-(4-chlorobenzyl)-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid 
• 571170-89-3 [5-bromo-4-(4-chloro-benzyl)-7-fluoro-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl]-acetic acid methyl ester 
• 393509-04-1 [5-bromo-4-(4-chlorobenzyl)-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid 
• 936337-07-4 methyl [(3R)-4-(4-chlorobenzyl)-7-fluoro-5-acetyl-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetate 
• 794535-36-7 [5-acetyl-4-(4-chloro-benzyl)-7-fluoro-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl]-acetic acid 
• 571170-92-8 [4-(4-chloro-benzyl)-7-fluoro-5-methanesulfonyl-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl]-acetic acid methyl ester 
• 571170-77-9 laropiprant 
• 794535-32-3 (+/-)-{4-[1-(4-chlorophenyl)ethyl]-7-fluoro-5-(methanesulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl}acetic acid 

Relevant articles and documents

Method of Treating Pathological Blushing

A method of treating pathological blushing is disclosed wherein the patient is administered a DP receptor antagonist. Compositions containing DP antagonists are also included.

METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS

A method of treating atherosclerosis is disclosed wherein nicotinic acid or another nicotinic acid receptor agonist is administered to the patient in combination with a DP receptor antagonist. The DP receptor antagonist is administered to reduce, prevent

NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT

The present invention encompasses compounds of Formula (I); as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating dyslipidemias. Pharmaceutical compositions and methods of use are also included.